Navigation Links
Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
Date:6/25/2008

SA), and has rapidly become one of the most common causes of skin and soft tissue infections among otherwise healthy people in the community. Staphylococcus aureus and CA-MRSA are causative pathogens for respiratory tract infections such as community acquired pneumonia (CAP). The CA-MRSA strain can attack and destroy white blood cells that normally help fight infections and can be even more aggressive than the hospital associated MRSA infections. Although the early strains of CA-MRSA strains were susceptible to most antimicrobials, bacterial resistance has increased, creating a need for new antibiotics that can cover the emerging deadly CA-MRSA strain.

The aim of the study reported in the paper was to compare the antimicrobial activity of cethromycin with three other macrolides (azithromycin, clarithromcin and erythromycin) and one lincosamide (clindamycin) against the 170 MRSA USA300 isolates that are contained in the Center for Biological Defense collection at the University of South Florida.

Cethromycin was shown to be effective against all 170 isolates, achieving an MIC range of < / = 0.002-0.125 mg/L, whereas the MIC50 and MIC90 were both < / = 0.002 mg/L. In addition, cethromycin demonstrated a MBC range of < / = 0.002-1.0 mg/L, with the MBC50 of < / = 0.002 mg/L and the MBC90 of < / = 0.008 mg/L. Of the 170 CA-MRSA isolates, 169 (99.4%) were intermediate or resistant to at least one macrolide. In contrast, 164 (96.5%) isolates were susceptible to clindamycin. Only six (3.5%) isolates demonstrated either constitutive resistance [4 (2.4%)] or inducible resistance [2 (1.2%)] to clindamycin. Against 10 erythromycin-susceptible isolates, the cethromycin MIC and MBC ranges were < / = 0.002-0.008 mg/L, compared with the MIC range of < / = 0.002-0.25 mg/L and MBC range of < / = 0.002-1.0 mg/L obtained with the erythromycin-resistant isolates. MIC50 and MBC50 values, as well as MIC90 and MBC90 values, did not change regardless of erythromycin susceptibil
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

3

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
6. Vaccine Study in New England Journal of Medicine Wrong in Concluding Mercury Exposures are Harmless, States SafeMinds
7. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 2Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 3Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 4Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 5Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 6Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 7Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 8Amgen Presents Data From First Nplate(R) Study in Children With Chronic ITP 9CompuCyte Announces the Release of Four-Laser Imaging Cytometers 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 1Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 2Andrews Institute for Orthopaedics and Sports Medicine Now Providing Free Orthopaedic Exams and Assessments on Saturday Mornings to Student Athletes 55929 3U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 1U S Labor Department announces dates for 4th annual Drug Free Work Week 55926 2Empire Blue Cross Blue Shield Awarded NCQAs Accreditation Status of Excellent 55923 1Empire Blue Cross Blue Shield Awarded NCQAs Accreditation Status of Excellent 55923 2